skip to main content

PENTOCLO ORN — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

ModerateHead & Neck CancerPENTOCLO ORNSCE Medical Oncology

A 60-year-old woman with advanced head and neck cancer develops osteoradionecrosis of the mandible refractory to conservative management. She is offered pentoxifylline + tocopherol (vitamin E). What is the evidence for this combination?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: D — The PENTOCLO regimen (pentoxifylline 400 mg BD + tocopherol 1000 IU daily ± clodronate) has shown efficacy in treating radiation-induced fibrosis including osteoradionecrosis — pentoxifylline is a methylxanthine with anti-fibrotic and anti-inflammatory properties; this approach is supported by observational data and small RCTs

The PENTOCLO regimen (pentoxifylline + tocopherol ± clodronate, Delanian et al) demonstrated efficacy in radiation-induced fibrosis, including ORN, in several studies. Pentoxifylline has vasodilatory, anti-inflammatory and anti-fibrotic properties. Tocopherol (vitamin E) provides antioxidant protection. Combined they show synergistic anti-fibrotic activity. Treatment duration is typically 6-24 months. Complete resolution of ORN is achieved in approximately 60-89% of cases. This is a well-established treatment in radiation oncology/oral surgery, though large RCT data is limited.

Reference: NICE NG36; ESMO H&N Survivorship; Delanian et al IJROBP 2004; Patel et al Head Neck 2021